Researchers demonstrate AI-enhanced MRI's potential in diagnosing endometrial cancer, achieving superior accuracy and ...

Seeing the disappointing post ESMO selloff (across a number of companies ... The impact of AbbVie's Elahere is misrepresented in my eyes, as NCCN guidelines recommend its use with Avastin in ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

(Image Credits: Pexels) The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated this month to recommend ribociclib (Kisqali) as a Category 1 preferred ...

Precision genomics company, Nonacus Ltd, has launched GALEASTM uPCR ESR1, an ultrasensitive qPCR (uPCR) assay developed to detect eleven mutations in the ESR1 gene which are known to be associated ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Thank you for taking time out of your very busy schedule to join the FY ‘24 Q2 earnings announcement by Takeda. I’m the master of ceremony, Head of IR. My name is O’Reilly. Thank you for this ...

In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.

In September, Incyte presented late-breaking Phase 3 results for retifanlimab (Zynyz ®) and initial data from the Phase 1 ...